Literature DB >> 32732182

Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.

V Benzecry1,2, V Pravettoni3, G Segatto1,3, A V Marzano1,2, S Ferrucci2.   

Abstract

Entities:  

Keywords:  Asthma; Atopic dermatitis; Dupilumab; Hypereosinophilia; IL-4/IL-13

Mesh：

Substances：

Year:  2020        PMID： 32732182     DOI： 10.18176/jiaci.0614

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN： 1018-9068            Impact factor:   4.333


× No keyword cloud information.
  4 in total

Review 1.  Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13.

Authors:  Corrado Pelaia; Giulia Pelaia; Claudia Crimi; Angelantonio Maglio; Giuseppe Armentaro; Cecilia Calabrese; Angela Sciacqua; Luca Gallelli; Alessandro Vatrella
Journal:  Vaccines (Basel)       Date:  2022-06-19

2.  Study of Hypersensitivity to Malassezia furfur in Patients with Atopic Dermatitis with Head and Neck Pattern: Is It Useful as a Biomarker and Therapeutic Indicator in These Patients?

Authors:  Francisco José Navarro-Triviño; Ángela Ayén-Rodríguez
Journal:  Life (Basel)       Date:  2022-02-16

Review 3.  Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets.

Authors:  Corrado Pelaia; Enrico Heffler; Claudia Crimi; Angelantonio Maglio; Alessandro Vatrella; Girolamo Pelaia; Giorgio Walter Canonica
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

4.  Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome.

Authors:  Xiaoman Du; Yudi Chen; Jianmin Chang; Xuelin Sun; Yue Zhang; Meng Zhang; Marcus Maurer; Yanming Li; Zuotao Zhao; Xunliang Tong
Journal:  JAAD Case Rep       Date:  2022-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.